P53和C-erbB-2在乳腺癌中的表达及意义

目的 分析研究P^53和C—erbB-2在乳腺癌中的表达与转移及预后的关系。方法 免疫组化法测定93例原发性乳腺癌中P^53和C—erbB-2表达情况。结果 P^53和C—erbB-2在乳腺癌中阳性表达率分别为55.9％（52／93）和40.9％（38／93），其阳性表达率随着临床分期增加和腋窝淋巴结转移数目的增加而增加，差异有显著性（P〈0．05）；P^53和C-erbB-2共同阳性表达与淋巴结转移差异有显著性（P〈0．05）。结论 P^53、C—erbB-2是判断乳腺癌预后的有效指标，联合检测P^53和C—erbB-2可指导临床综合治疗。

Expression of P53 and C-erbB-2 in Primary Breast Carcinoma and Its Clinical Significance

Objective To investigate the expression of P~(53) and C-erbB-2 and the relation to metastasis and prognosis of primary breast carcinoma. Methods The expression of P~(53) and C-erbB-2 were detected by immunochemical S-P methods in 93 cases of primary breast carcinoma. Results The expression rate of P~(53) and C-erbB-2 were 55.9%(52/93) and 40.9%(38/93) respectively. The positive rate of P~(53) and C-erbB-2 increased with the number of metastasis lymph node and clinical stage, and there was a significant difference(P<0.05). The Co-expression of P~(53) and C-erbB-2 related to lymph node metastasis significantly (P<0.05). Conclusions P~(53) and C-erbB-2 are useful prognostic factors in patients with breast carcinoma. The combined detection of P~(53) and C-erbB-2 has important significance for clinical therapy.